|1.||Kaufman, Keith D: 18 articles (07/2015 - 02/2008)|
|2.||Goldstein, Barry J: 14 articles (03/2015 - 03/2009)|
|3.||Engel, Samuel S: 13 articles (07/2015 - 01/2010)|
|4.||Davies, Michael J: 13 articles (03/2014 - 12/2005)|
|5.||Kaufman, K D: 12 articles (06/2015 - 07/2008)|
|6.||Goldstein, B J: 11 articles (06/2015 - 03/2010)|
|7.||Golm, Gregory T: 11 articles (06/2015 - 01/2010)|
|8.||Engel, S S: 9 articles (10/2015 - 09/2008)|
|9.||Wagner, John A: 9 articles (01/2012 - 12/2005)|
|10.||Terauchi, Yasuo: 8 articles (08/2015 - 01/2010)|
|1.||Type 2 Diabetes Mellitus (MODY)
08/01/2011 - "Sitagliptin combination therapy for 14 weeks significantly improved glycemic control and was well-tolerated in Korean subjects with type 2 diabetes mellitus."
11/01/2006 - "Sitagliptin significantly improved glycaemic control and was well tolerated in patients with type 2 diabetes mellitus who had inadequate glycaemic control on exercise and diet."
06/01/2011 - "Response: predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus (diabetes metab j 2011;35:159-65)."
06/01/2011 - "Letter: predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus (diabetes metab j 2011;35:159-65)."
04/01/2011 - "Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus."
|2.||Body Weight (Weight, Body)
06/01/2015 - "In this analysis of elderly patients with T2DM, compared with sulfonylurea, sitagliptin provided similar glycaemic efficacy with less hypoglycaemia and with body weight loss."
02/01/2014 - "Sitagliptin was generally well tolerated in clinical trials, had a low risk of hypoglycaemia (although this depends on background therapy) and had a neutral effect on body weight. "
08/01/2015 - "Most patients (n = 809) received sitagliptin at a dose of 50 mg. In the 1,004 patients, HbA1c decreased by 0.74% (6 mmol/mol) and body weight increased by 0.1 kg after 6 months of combination therapy. "
06/01/2015 - "Sitagliptin was weight-neutral; while the between-group difference in change from baseline in body weight was statistically significant, the modest difference may not be clinically meaningful. "
06/01/2015 - "Significantly more patients on sitagliptin than on sulfonylureas achieved a composite end-point of >0.5% HbA1c reduction with no reported hypoglycaemia or increase in body weight (44.1% vs. 16.0%; p < 0.001). "
07/01/2011 - "Sitagliptin decreased the average glycemic level and also improved 24-h glycemic fluctuation, including postprandial hyperglycemia."
06/01/2015 - "The intervention group included patients who had received sitagliptin soon after hyperglycemia developed. "
06/01/2015 - "Sitagliptin, a DPP-4 inhibitor, was a commonly used therapy for hyperglycemia after PT due to its wide availability and coverage. "
08/01/2014 - "Our findings suggest that, in addition to its well-known hypoglycemic action, sitagliptin may also have beneficial effects on hyperglycemia-induced vascular changes in an endotheium-dependent manner. "
03/01/2014 - "Combined therapy of WJ-MSCs and sitagliptin can effectively ameliorate hyperglycemia, promote regeneration of islet β cells and suppress generation of islet α cells in diabetic rats, presenting a new therapy for type 2 diabetes although the exact mechanisms are unclear. "
|4.||Hypoglycemia (Reactive Hypoglycemia)
01/01/2014 - "Sitagliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor, has a low incidence of hypoglycemia, is weight neutral, and, in a small study, did not affect immunosuppressant levels. "
10/01/2013 - "Moreover, severe hypoglycemia occurred in three clinical trials using sitagliptin, but in two of these trials this phenomenon has been previously described only in the drug application data in the US. "
08/01/2012 - "Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study."
01/01/2012 - "This study, approved by the institutional review board of Hanzoumon Diabetes City Atlas Clinic, examined whether DPP-4 inhibitor sitagliptin could safely achieve good glycemic control without severe hypoglycemia by employing the "added food" concept. "
10/20/2015 - "Review: In patients with type 2 diabetes who fast, sitagliptin reduces hypoglycemia more than sulfonylurea."
|5.||Weight Loss (Weight Reduction)
05/01/2014 - "In head-to-head clinical trials, GLP-1RAs provided greater glycaemic control, weight loss and overall treatment satisfaction vs. the DPP-4 inhibitor sitagliptin. "
09/01/2015 - "Dulaglutide doses provided superior glycaemic control and dulaglutide 1.5 mg resulted in greater weight reduction versus sitagliptin at 104 weeks, with acceptable safety."
09/01/2015 - "Weight loss was greater with dulaglutide 1.5 mg (p < 0.001) and similar with 0.75 mg versus sitagliptin (2.88 ± 0.25, 2.39 ± 0.26 and 1.75 ± 0.25 kg, respectively). "
06/01/2015 - "Overall, addition of sitagliptin 100 mg once daily resulted in 5.5 mmol/mol (0.5%) HbA1c reduction (P < 0.001) and 0.8 kg weight reduction at 1 year (P < 0.001). "
03/01/2011 - "Overall treatment satisfaction, calculated by adding satisfaction scores for `current treatment', `convenience', `flexibility', `understanding', `recommend', and `continue', improved in all groups at 26 weeks; greater improvement with liraglutide (4.35 and 3.51 vs. 2.96; P = 0.03 for liraglutide 1.8 mg vs. sitagliptin) may reflect greater HbA1c reduction and weight loss. "
|3.||Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)
|9.||glargine (insulin glargine)
|10.||Glucagon-Like Peptide 1 (GLP 1)
|1.||Transplantation (Transplant Recipients)